Share Twitter LinkedIn Facebook Email Sara M. Tolaney, MD, MPH, talks about whether CDK4/6 inhibitors can be used interchangeably at Annual Meeting 2018.
Enhertu DESTINY-Breast06 Phase III Study the Impact on HR-Positive, HER2-Low Metastatic Breast Cancer Revealed Breast 4 Mins Read
Strategizing Personalized Breast Cancer Treatment: A Promising Overview of Advances and Clinical Applications [39 SLIDES] Breast 4 Mins Read